NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patients

World Journal of Gastroenterology

Volumn 19, Issue 8, 2013, Pages 1219-1229

  Treeprasertsuk, Sombat ^a   Björnsson, Einar ^b   Enders, Felicity ^c   Suwanwalaikorn, Sompongse ^a   Lindor, Keith D ^d  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c MAYO CLINIC   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Liver complications; Mortality; Nonalcoholic fatty liver disease fibrosis score; Prognostic predictor

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLITAZONE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ASCITES; COHORT ANALYSIS; DEATH; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART DISEASE; HEPATOPULMONARY SYNDROME; HUMAN; HUMAN TISSUE; ISCHEMIC HEART DISEASE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PARACENTESIS; PREDICTION; REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 84874627945     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i8.1219     Document Type: Review

References (37)

1. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol 2007; 17: 863-869 [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013]
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
3. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Longterm followup of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/ hep.21327]
4. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a populationbased cohort study. Gastroenterology 2005; 129: 113-121 [PMID: 16012941 DOI: 10.1053/ j.gastro.2005.04.014]
5. Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 28: 503-522 [PMID: 18532991 DOI: 10.1111/ j.1365-2036.2008.03752.x]
6. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a followup study of fortytwo patients for up to 21 years. Hepatology 1990; 11: 74-80 [PMID: 2295475 DOI: 10.1002/hep.1840110114]
7. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-2047 [PMID: 14499785 DOI: 10.1111/j.1572-0241.2003.07659.x]
8. Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004; 40: 820-826 [PMID: 15382171]
9. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-854 [PMID: 17393509 DOI: 10.1002/hep.21496]
10. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008; 57: 1441-1447 [PMID: 18390575 DOI: 10.1136/gut.2007.146019]
11. Nakano M, Murohisa T, Imai Y, Hiraishi H. [Validity of the NAFLD fibrosis score in a Japanese population]. Nihon Shokakibyo Gakkai Zasshi 2012; 109: 751-759 [PMID: 22688100]
12. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005; 42: 132-138 [PMID: 15629518 DOI: 10.1016/ j.jhep.2004.09.012]
13. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996; 71: 266-274 [PMID: 8594285]
14. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438 [PMID: 7382552]
15. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, Caballería J, Rodés J, Rozman C. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-128 [PMID: 3804191 DOI: 10.1002/hep.1840070124]
16. Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005; 33: 68-71 [PMID: 16214395 DOI: 10.1016/ j.hepres.2005.09.006]
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847 [PMID: 9603539 DOI: 10.1161/01.CIR.97.18.1837]
18. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417 [PMID: 20633946 DOI: 10.1016/j.jhep.2010.05.004]
19. Lebrec D, Vinel JP, Dupas JL. Complications of portal hypertension in adults: a French consensus. Eur J Gastroenterol Hepatol 2005; 17: 403-410 [PMID: 15756092 DOI: 10.1097/000 42737-200504000-00003]
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421 [PMID: 12485966]
21. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366: 1059-1062 [PMID: 16182882 DOI: 10.1016/S0140-6736(05)67402-8]
22. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Longterm followup of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238 [PMID: 19049831 DOI: 10.1016/j.cgh.2008.11.005]
23. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419 [PMID: 10348825 DOI: 10.1016/ S0016-5085(99)70506-8]
24. Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological followup study. J Hepatol 2007; 47: 135-141 [PMID: 17400325 DOI: 10.1016/j.jhep.2007.02.013]
25. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229, 1224-1229, [PMID: 19559819 DOI: 10.1111/j.1365-2036.2004.01888.x]
26. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A, Yesilova Z, Gulsen M, Dagalp K. Metformin in the treatment of patients with nonalcoholic steatohepatitis. Ali-ment Pharmacol Ther 2004; 19: 537-544 [PMID: 14987322]
27. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database Syst Rev 2007; (1): CD005166 [PMID: 17253544]
28. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004; 126: 1287-1292 [PMID: 15131789 DOI: 10.1053/j.gastro.2004.02.015]
29. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695 [PMID: 15789367 DOI: 10.1002/hep.20671]
30. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11: 272-278 [PMID: 19627660]
31. Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, Takahashi S, Chayama K. Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: An openlabel, pilot study. Hepatol Res 2012; 42: 1065-1072 [PMID: 22583925 DOI: 10.1111/j.1872-034X.2012.01034.x]
32. Nseir W, Mograbi J, Ghali M. Lipidlowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies. Dig Dis Sci 2012; 57: 1773-1781 [PMID: 22419057 DOI: 10.1007/s10620-012-2118-3]
33. Ajamieh H, Farrell G, Wong HJ, Yu J, Chu E, Chen J, Teoh N. Atorvastatin protects obese mice against hepatic ischemiareperfusion injury by Tolllike receptor-4 suppression and endothelial nitric oxide synthase activation. J Gastroenterol Hepatol 2012; 27: 1353-1361 [PMID: 22432744 DOI: 10.1111/ j.1440-1746.2012.07123.]
34. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998; 97: 946-952 [PMID: 9529261]
35. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-321 [PMID: 9228438]
36. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011; 56: 35-45 [PMID: 20464495 DOI: 10.1007/ s10620-010-1241-2]
37. Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St Sauver J, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-950 [PMID: 22299674 DOI: 10.1111/j.1478-3231.2011.02753.x]